TIDMHCM
RNS Number : 6999I
Hutchison China Meditech Limited
15 December 2020
Grant of Share Options under Share Option Scheme
London: Tuesday, December 15, 20 20 : Hutchison China MediTech
Limited ("Chi-Med") (Nasdaq /AIM : HCM) announces that on December
14, 20 20, it granted share options under the Share Option Scheme
conditionally adopted by Chi-Med at its Annual General Meeting on
April 24, 2015 (the "Share Option Scheme"). The scheme limit of the
Share Option Scheme was refreshed on April 27, 2020.
Chi-Med granted share options under its Share Option Scheme to
employees to subscribe for a total of 1,535,580 Ordinary Shares
represented by 307,116 American Depositary Shares ("ADSs") (each
equating to five Ordinary Shares) subject to the acceptance of the
grantees. Details of such share options granted prescribed are as
follows:
Date of grant : December 14 , 2020
Exercise price of share options : US$29 per ADS
granted
Number of share options granted : 1,535,580 represented by 307,116
ADSs (five share options shall entitle
the holder thereof to subscribe
for one ADS)
Closing market price of ADSs : US$29 per ADS
on the date of grant
Validity period of the share : From December 14, 2020 to December
options 13, 2030
Among the share options granted, a total of 58,570 share options
represented by 11,714 ADSs were granted to Mr Christian Hogg and Dr
Weiguo Su (Executive Directors of the Company), being persons
discharging managerial responsibility under the EU Market Abuse
Regulation as follows:-
Grantee Number of share options granted
Mr Christian Hogg (Executive Director 39,610 Ordinary Shares represented
and Chief Executive Officer) by 7,922 ADSs
Dr Weiguo Su (Executive Vice President 18,960 Ordinary Shares represented
and Chief Scientific Officer) by 3,792 ADSs
The notification set out below is provided in accordance with
the requirements of the EU Market Abuse Regulation.
(a) Mr Christian Hogg
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Christian Hogg
------------------------------------------------------- -----------------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Executive Officer
------------------------------------------------------- -----------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- -----------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
--------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
------------------------------------------------------- -----------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
--------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Option over American Depositary Share (each
instrument equating to five Ordinary Shares of US$0.10)
Identification code
Option over American Depositary Share with ADS
ISIN: US44842L1035
------------------------------------------------------- -----------------------------------------------------
b) Nature of the transaction Grant of options in respect of 39,610 Ordinary
Shares represented by 7,922 ADSs under the
Share Option Scheme.
The share options granted are exercisable subject
to a vesting schedule of 25% on each of
the first, second, third and fourth anniversaries
of the effective date of grant.
------------------------------------------------------- -----------------------------------------------------
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 7,922
-----------------
------------------------------------------------------- -----------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------------------------------- -----------------------------------------------------
e) Date of the transaction 2020-12-14
------------------------------------------------------- -----------------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------------------------- -----------------------------------------------------
(b) Dr Weiguo Su
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Weiguo Su
------------------------------------------------------- -----------------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Scientific Officer
------------------------------------------------------- -----------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- -----------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
--------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
------------------------------------------------------- -----------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
--------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Option over American Depositary Share (each
instrument equating to five Ordinary Shares of US$0.10)
Identification code
Option over American Depositary Share with ADS
ISIN: US44842L1035
------------------------------------------------------- -----------------------------------------------------
b) Nature of the transaction Grant of options in respect of 18,960 Ordinary
Shares represented by 3,792 ADSs under the
Share Option Scheme.
The share options granted are exercisable subject
to a vesting schedule of 25% on each of
the first, second, third and fourth anniversaries
of the effective date of grant.
------------------------------------------------------- -----------------------------------------------------
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 3,792
-----------------
------------------------------------------------------- -----------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------------------------------- -----------------------------------------------------
e) Date of the transaction 2020-12-14
------------------------------------------------------- -----------------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------------------------- -----------------------------------------------------
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage,
biopharmaceutical company committed, over the past twenty years, to
the discovery and global development of targeted therapies and
immunotherapies for the treatment of cancer and immunological
diseases. It has a portfolio of nine cancer drug candidates
currently in clinical studies around the world and extensive
commercial infrastructure in its home market of China. For more
information, please visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
Chi-Med@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97
83 6894 (Mobile), y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGPGWWPUPUUBA
(END) Dow Jones Newswires
December 15, 2020 04:45 ET (09:45 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024
